Successful treatment of an acyclovir- and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir.
LoPresti
A E
AE
Department of Internal Medicine and Virology Laboratory, Hackensack University Medical Center, New Jersey, USA.
Levine
J F
JF
Munk
G B
GB
Tai
C Y
CY
Mendel
D B
DB
D000212:Acyclovir / Q000494:pharmacology*; D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology*; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D017245:Foscarnet / Q000494:pharmacology*; D006561:Herpes Simplex / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000150:complications; D008297:Male; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000494:pharmacology*
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D017245:Foscarnet; D003596:Cytosine; D000077404:Cidofovir; D000212:Acyclovir